Examples of using Angiox in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Angiox?
Angiox is a white to off-white powder in a glass vial.
What is Angiox used for?
Other information about Angiox.
Why has Angiox been approved?
Do not use Angiox.
Angiox is not to be used after the expiry date which is stated on the label and carton after‘EXP.
If you forget to have Angiox.
Bivalirudin(Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor DTI.
There is no relevant indication for use of Angiox in children or adolescents.
Angiox should be given by a doctor who has experience in the emergency care of patients with heart problems or in carrying out procedures on the heart.
For the full list of all side effects reported with Angiox, see the package leaflet.
In PCI, Angiox has been compared withanother type of anticoagulant, a heparin, in two studies involving a total of almost 10,000 adults.
Clinical trials in a small number of patientshave provided limited information about the use of Angiox in patients with HIT/ HITTS.
The recommended starting dose of Angiox for patients with ACS is an intravenous bolus of 0.1 mg/ kg followed by an infusion of 0.25 mg/ kg/ h.
The European Commission granted amarketing authorisation valid throughout the European Union for Angiox to The Medicines Company UK Ltd on 20 September 2004.
The CHMP concluded that Angiox is an acceptable substitute for heparin during PCI and in the treatment of unstable angina and myocardial infarction.
The Committee for Medicinal Products for Human Use(CHMP) concluded that Angiox is an acceptable substitute for heparin in the treatment of ACS and during PCI.
The company that makes Angiox will provide all doctors who are expected to prescribe the medicine with training and educational materials on how to use it correctly, including dosing instructions.
The safety and efficacy of a bolus only dose of Angiox has not been evaluated and is not recommended even if a short PCI procedure is planned.
Angiox contains bivalirudin, a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin.
When used to treat unstable angina ormyocardial infarction without ST segment elevation, Angiox, given with or without a GPI, was as effective as the combination of heparin and a GPI in preventing deaths, heart attacks and revascularisations.
Angiox is used to treat adults with‘ acute coronary syndromes'(ACS, reduced blood flow to the heart), such as unstable angina(a type of chest pain that varies in severity) or myocardial infarction(heart attack) without‘ ST segment elevation' an abnormal reading on the electrocardiogram or ECG.
Bleeding is more likely to occur when Angiox is used in combination with other anticoagulant or antithrombotic medicines see section 2‘Taking other medicines.
Patients can be started on Angiox 30 minutes after discontinuation of unfractionated heparin given intravenously, or 8 hours after discontinuation of low molecular weight heparin given subcutaneously.
The active substance in Angiox, bivalirudin, is a synthetic substance originally derived from hirudin, the anticoagulant substance produced by leeches.
In patients undergoing PCI, Angiox was as effective as heparin in all measures, except major bleeding, for which it was significantly better than heparin.
If bleeding occurs, treatment with Angiox will be stopped.• Before the start of the injection or infusion, the doctor will tell you about the signs of allergic reaction.
When used to treat ACS, Angiox, taken with or without a GPI, was as effective as the standard treatment in preventing the overall number of new events(deaths, heart attacks or revascularisations) after 30 days and after a year.
The recommended dose of Angiox for patients undergoing PCI is an intravenous bolus of 0.75 mg/ kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/ kg body weight/ hour for at least the duration of the procedure.